MiR-221 Alleviates the Ox-LDL-Induced Macrophage Inflammatory Response Via the Inhibition of DNMT3b-Mediated NCoR Promoter Methylation
Overview
Pathology
Affiliations
Atherosclerosis (AS) is a chronic inflammatory disease, and macrophages play a key role in all phases of AS. Recent studies have shown that miR-221 is a biomarker for AS and stroke; however, the role and mechanism of miR-221 in AS are unclear. Herein, we found that miR-221 and NCoR levels were decreased in ox-LDL-treated THP-1-derived macrophages. In contrast, DNMT3b, IL-6, and TNF- expression levels were increased under these conditions. Upregulation of miR-221 or NCoR could partially inhibit ox-LDL-induced IL-6 and TNF- expression. Further studies showed that DNMT3b was a target of miR-221. DNMT3b inhibition also suppressed IL-6 and TNF- expression and increased NCoR expression in the presence of ox-LDL. Moreover, DNMT3b was involved in ox-LDL-induced DNA methylation in the promoter region of NCoR. These findings suggest that miR-221 suppresses ox-LDL-induced inflammatory responses via suppressing DNMT3b-mediated DNA methylation in the promoter region of NCoR. These results provide a rationale for using intracellular miR-211 as a possible antiatherosclerotic target.
MicroRNAs Regulate Function in Atherosclerosis and Clinical Implications.
Li Z, Zhao Y, Suguro S, Suguro R Oxid Med Cell Longev. 2023; 2023:2561509.
PMID: 37675243 PMC: 10480027. DOI: 10.1155/2023/2561509.
Deng Q, Li H, Yue X, Guo C, Sun Y, Ma C Cell Death Dis. 2023; 14(8):542.
PMID: 37607939 PMC: 10444762. DOI: 10.1038/s41419-023-06054-x.
Qin W, Spek C, Scicluna B, van der Poll T, Duitman J Respir Res. 2022; 23(1):162.
PMID: 35725453 PMC: 9210707. DOI: 10.1186/s12931-022-02088-5.
Epigenetic regulation of inflammatory factors in adipose tissue.
Jung B, Kang S Biochim Biophys Acta Mol Cell Biol Lipids. 2021; 1866(11):159019.
PMID: 34332076 PMC: 8719460. DOI: 10.1016/j.bbalip.2021.159019.
DNA Methylation in Atherosclerosis: A New Perspective.
Zhang Y, Mei J, Li J, Zhang Y, Zhou Q, Xu F Evid Based Complement Alternat Med. 2021; 2021:6623657.
PMID: 34257689 PMC: 8249120. DOI: 10.1155/2021/6623657.